Sequential designs for individualized dosing in phase I cancer clinical trials.
Contemp Clin Trials
; 63: 51-58, 2017 12.
Article
en En
| MEDLINE
| ID: mdl-27592121
ABSTRACT
This paper addresses dose finding in clinical trials where individuals exhibit biologic characteristics that alter the toxicity risks of the individuals. In these situations, instead of determining a dose that works for every patient, the trial aims to identify a dosing algorithm that prescribes dose according to the patient's biomarker or pharmacokinetic expression. Specifically, we aim to dose patients around a pre-specified level of area under the curve of irinotecan concentration using the patients' baseline phenotypes that predict drug clearance. We propose least squares recursion procedures to estimate the dosing algorithm sequentially with an aim to treat patients in the trial around the true unknown dosing algorithm, and introduce a novel application of an eigenvalue theory that guarantees convergence to the true dosing algorithms. Our simulation study demonstrates that using an eigenvalue constraint improves the efficiency of the recursion by as large as 40%, while concentrating in-trial patient allocation around the true dosing algorithm. We also provide practical guidance on design calibration, and design future irinotecan studies based on data from our first trial.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Simulación por Computador
/
Ensayos Clínicos Fase I como Asunto
/
Relación Dosis-Respuesta a Droga
/
Neoplasias
/
Antineoplásicos
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Contemp Clin Trials
Asunto de la revista:
MEDICINA
/
TERAPEUTICA
Año:
2017
Tipo del documento:
Article